证券代码：300451 证券简称：创业软件 编号：2018-004 创业软件股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|-----------------------------------------------|-------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | █ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称 | | 中银基金、广发证券、星石投资、中邮基金、中金资管、东 北证券、人保资产（以上排名不分先后） | | | | | | 时间 地点 | 2018 年 4 月 26 日 创业智慧大厦 5 | 楼会议室 | | | | | | 上市公司接待人 员姓名 | 董事会秘书 ...

Financial Performance - In the first three quarters of 2018, the company achieved operating revenue of 800 million yuan, a year-on-year increase of 5.37% [2] - The net profit attributable to shareholders was 112 million yuan, reflecting a significant year-on-year growth of 65.94% [2] - The rapid growth is primarily attributed to the continuous development of the company's healthcare information software business [2] Strategic Planning - The company plans to change its name to "Chuangyi Huikang Technology Co., Ltd." to better reflect its focus on smart health [3] - Starting in 2019, the company will reorganize its traditional healthcare information business and innovative business into three major sectors: healthcare information, IoT in healthcare, and healthcare internet [3][4] - The healthcare information sector will focus on HIT (Health Information Technology) and smart healthcare [3] Growth Opportunities - The electronic medical record (EMR) business is expected to grow significantly due to new policies mandating EMR application levels in hospitals [4] - The company has secured a major contract worth 52.8 million yuan for the information construction project of Zibo Central Hospital, indicating a trend towards large-scale upgrades in hospital information systems [4] - There is a growing market opportunity as smaller regional software companies struggle to meet new healthcare information demands [5] Project Updates - The Zhongshan project is set to be completed by the end of December 2018, with a ten-year operational phase planned for 2019 [5] - The company has over 1 billion yuan in orders based on big data architecture [5] - Current order amounts are approximately 500 million yuan, with total actual orders around 700 million yuan, indicating a strong order growth rate [5] Talent Development - The company has increased its professional staff by over 300 in 2017 for key technologies in big data and artificial intelligence [6] - Collaboration with Zhejiang University has led to the establishment of a postdoctoral workstation, attracting talented graduates [6]

编号：2021-006 投资者关系活动 █特定对象调研 □分析师会议 类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 源乘投资、创金合信基金、泓澄投资、国泰君安、中庚基金致 君资产、Oasis Capital、申万宏源、中意资产、前润并投基金、 建信基金、华夏未来、中泰证券、晟盟资管、迎水投资、中信 资管、中信自营、煜德投资、兴业基金、国信弘盛、拾贝投资、 明河投资、金库资本、仁桥资产、上投摩根基金、鹏扬基金、 英睿投管、华夏基金、恩宝资管、安信证券、瑞颐投管、高投 产控、江苏瑞华、大正十方基金、天安人寿、安信基金、天虫 资本、中融人寿、中泰国际、东北证券、九泰基金、涌悦资产、 英大资产、汇泉投资、中天证券、稷定资本、和谐汇一资管、 上海青沣资管、财通基金、博时基金、万联自营、中金资管、 财通资管、中银基金、庶达资管、人保养老、东莞市榕果投管、 谦宏投资、中润投资、远策投资、光大保德信、景富投资、瑞 新资管、钰阳投资、泽铭投资、诺德基金、盛世景、华福证券 资管、东吴基金、长江资管、中国对外经济贸易信托有限公司、 太平基金、人保资产、南方睿 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥358,178,191.63, a decrease of 16.99% compared to the same period last year[6]. - The net profit attributable to shareholders for Q3 2022 was ¥69,412,464.24, down 20.68% year-on-year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥66,446,966.31, a decrease of 23.99% compared to the previous year[6]. - Total operating revenue for the third quarter was CNY 1,138,576,105.77, a decrease of 5.86% compared to CNY 1,209,502,704.67 in the same period last year[36]. - The net profit for the third quarter was 171,035,182.36, a decrease of 26% compared to 231,345,933.42 in the previous year[40]. - The total profit amounted to 187,710,734.04, down from 256,212,781.35, reflecting a decline of approximately 27%[40]. - Operating profit decreased to 184,043,324.72 from 256,603,951.33, indicating a drop of about 28%[40]. - Basic earnings per share were 0.11, down from 0.15, reflecting a decrease of about 27%[42]. - The company's total comprehensive income attributable to the parent company was 171,035,182.36, down from 231,345,933.42, indicating a decline of approximately 26%[41]. Assets and Liabilities - The total assets at the end of the reporting period were ¥5,848,385,891.48, an increase of 4.26% from the end of the previous year[6]. - Total assets reached CNY 5,848,385,891.48, compared to CNY 5,609,578,430.23 at the beginning of the year, indicating growth in asset base[32]. - Total liabilities increased to CNY 1,118,094,751.35 from CNY 1,010,278,633.60, reflecting higher financial obligations[35]. - The company's equity attributable to shareholders rose to CNY 4,697,242,940.25, compared to CNY 4,561,801,820.95, showing improved shareholder value[35]. Cash Flow - The company reported a net cash flow from operating activities of -¥178,849,931.62 for the year-to-date, reflecting a 28.16% increase in cash outflow compared to the previous year[6]. - The cash flow from operating activities showed a net outflow of -178,849,931.62, compared to -248,968,547.98 in the same period last year, representing an improvement[43]. - Cash inflow from operating activities totaled 937,387,271.90, up from 830,226,536.25, marking an increase of approximately 13%[43]. - The company reported a cash and cash equivalents balance of 1,254,807,152.95 at the end of the period, compared to 1,235,362,698.17 at the end of the previous year[46]. - Investment activities generated a net cash flow of 809,163,156.15, a significant decrease from 1,570,091,678.75 in the prior year[46]. - The company received cash from investment income totaling 14,209,859.56, an increase from 13,296,400.79 year-over-year[46]. Research and Development - The company’s R&D expenses increased by 55.95% year-on-year, indicating a significant investment in new product and technology development[10]. - Research and development expenses increased to CNY 149,697,194.79, up from CNY 136,146,832.70, reflecting a focus on innovation[36]. Shareholder Structure and Equity Incentives - The company reported a total of 206,690,519 restricted shares at the beginning of the period, with 1,826,565 shares released from restrictions during the quarter, resulting in 252,745,048 restricted shares at the end of the period[29]. - The company has 7,657,553 shares under the equity incentive plan, with 1,826,565 shares released from restrictions, leaving 5,830,988 shares still restricted[29]. - The company’s major shareholder, Ge Hang, had an initial restricted share count of 172,638,088, with 47,881,094 shares added to the restricted count, totaling 220,519,182 shares at the end of the period[23]. - The company’s top ten unrestricted shareholders include Philips (China) Investment Co., Ltd. with 155,003,087 shares, Zhejiang Xinsu Technology Co., Ltd. with 51,124,760 shares, and others totaling significant holdings[19]. - The company’s equity incentive plan allows for the release of restricted shares at a rate of 25% annually based on the previous year-end holdings for executives[23]. - The company’s total unrestricted shares held by the top ten shareholders account for a significant percentage of the total shares outstanding, indicating concentrated ownership[19]. - The company’s management has a structured plan for the release of restricted shares, ensuring alignment with long-term performance goals[23]. - The company is focused on maintaining a balance between incentivizing management and protecting shareholder interests through its equity incentive plan[29]. - The company’s financial strategy includes managing the release of restricted shares to optimize capital structure and shareholder value[29]. - The company’s performance metrics and shareholder structure are closely monitored to ensure compliance with regulatory requirements and to enhance investor confidence[19]. Operational Costs - Total operating costs amounted to CNY 898,731,935.85, down 5.02% from CNY 946,138,215.74 year-on-year[36]. - Cash and cash equivalents decreased to CNY 1,256,278,666.80 from CNY 1,619,154,719.36, indicating a reduction in liquidity[30]. - Accounts receivable rose to CNY 1,500,227,905.89, an increase of 19.92% from CNY 1,250,852,813.34[30]. - Inventory increased to CNY 268,136,499.11, up from CNY 240,505,018.58, suggesting potential challenges in sales or supply chain[30]. Strategic Focus - The company is focusing on market expansion and new product development as part of its strategic initiatives[34].

Business Focus and Strategy - The company reported a significant shift in its main business focus from product development and sales to system construction, service, and operation, including areas like smart healthcare and medical big data [10]. - The company aims to adjust its product development and market expansion strategies based on user demand and market competition to manage risks associated with innovative business expansion [10]. - The company is actively responding to national policy changes and macroeconomic conditions to maintain its market position and enhance its core competitiveness [25]. - The company is focused on continuous product innovation and market expansion to improve profitability amid uncertainties caused by the global pandemic [26]. - The company is enhancing its financial control measures to manage risks associated with resource limitations during its business expansion efforts [10]. Research and Development - The company plans to enhance R&D investment and strengthen collaboration with renowned universities and research institutions to mitigate technology and product development risks [6]. - The R&D department follows the CMMI5 software maturity development process, ensuring quality control and product testing throughout the development cycle [71]. - R&D investment for the first half of 2022 was 144.91 million yuan, an increase of 11.99% compared to the same period last year [77]. - The company has applied for 2 invention patents and 3 software copyrights during the reporting period, showcasing its commitment to innovation [86]. - The second-generation hardware device "Chuangye 5G Smart Gateway" has achieved mass production, enhancing the company's IoT solutions for healthcare institutions [86]. Financial Performance - The company's operating revenue for the first half of 2022 was ¥780,397,914.14, a slight increase of 0.31% compared to ¥778,007,750.65 in the same period last year [51]. - The net profit attributable to shareholders decreased by 28.77% to ¥101,516,847.62 from ¥142,513,537.57 year-on-year [51]. - The net profit after deducting non-recurring gains and losses was ¥107,502,433.08, down 7.50% from ¥116,217,305.76 in the previous year [51]. - The net cash flow from operating activities improved by 21.93%, reaching -¥189,123,434.61 compared to -¥242,234,432.39 in the same period last year [51]. - The basic earnings per share decreased by 22.22% to ¥0.07 from ¥0.09 in the previous year [51]. Market and Product Development - The company has established a comprehensive product system with over 300 self-developed products in the medical and health information technology sector [61]. - The "HuiKang Cloud 2.0" transformation strategy has been initiated, focusing on cloud-based solutions across various service scenarios including healthcare, insurance, and elderly care [61]. - The company is actively promoting the "Internet + Healthcare" model, with important products like the "Hybrid Cloud Internet Hospital Solution" and "Prescription Sharing Platform" [67]. - The company is focusing on the development of a smart healthcare ecosystem based on IoT technology, with products like the "Medical IoT Access Platform" and "Digital Ward" [68]. - The company employs a dual-layer sales system, combining product division sales with regional marketing centers to enhance market reach [70]. Operational Challenges and Risks - The company anticipates seasonal fluctuations in its operations, with project acceptance and payment concentrated in the second half of the year, particularly in Q4 [16]. - The company faces potential goodwill impairment risks from acquisitions and will implement comprehensive post-merger management to ensure the competitiveness of acquired entities [20]. - The company is committed to talent retention strategies, including establishing a postdoctoral workstation and implementing employee stock ownership plans to prevent core talent loss [19]. - The company emphasizes the importance of maintaining effective communication with clients to mitigate the impacts of the pandemic on operations and project development [26]. Shareholder and Equity Information - The company’s stock incentive plan included the unlocking of 623,171.2 shares, representing 0.40% of the total share capital [135]. - The total number of ordinary shareholders at the end of the reporting period was 37,057 [185]. - The total number of restricted shares at the beginning of the period was 212,606,331, with 6,231,712 shares released during the period [184]. - The number of shares held by the top shareholder, Ge Hang, is 220,519,182, representing 14.23% of total shares [185]. - The company did not distribute cash dividends or bonus shares for the half-year period, nor did it increase capital through reserves [134]. Investment and Fundraising - The total investment amount for the reporting period was 121,617,009.81, an increase of 254.76% compared to the previous period [105]. - The company raised a total of RMB 131,760.96 million through a private placement of 79,806,759 shares at RMB 16.51 per share, with a net amount of RMB 128,877.04 million after deducting fees [108]. - The total amount of raised funds invested during the reporting period was RMB 9,158.15 million, with a cumulative investment of RMB 83,716.43 million [109]. - The "Data Integration Driven" project has an investment commitment of RMB 68,502.34 million, with 61.54% of the investment completed by the end of the reporting period [110]. - The "Marketing Service System Expansion" project has an investment commitment of RMB 10,023.56 million, with 55.43% of the investment completed [113]. Corporate Governance and Compliance - The company has not engaged in any derivative investments during the reporting period [119]. - The company has not sold any significant assets during the reporting period [121]. - The company has not engaged in any entrusted loans during the reporting period [120]. - The company has maintained a clean record with no non-operating fund occupation by major shareholders or related parties [148]. - The company has not faced any administrative penalties related to environmental issues during the reporting period [142].

Financial Performance - The company's operating revenue for Q1 2022 was ¥462,990,891.86, representing a 15.11% increase compared to ¥402,209,573.15 in the same period last year[5] - The net profit attributable to shareholders for Q1 2022 was ¥92,246,842.09, a 2.08% increase from ¥90,363,704.15 year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥97,559,535.02, up 16.32% from ¥83,874,973.58 in the previous year[5] - Total operating revenue for the first quarter reached ¥462,990,891.86, an increase of 15.06% compared to ¥402,209,573.15 in the previous year[30] - The total profit amounted to 104,072,101.61, slightly up from 103,893,781.25, indicating a growth of about 0.18%[37] Assets and Equity - The company's total assets at the end of Q1 2022 were ¥5,714,284,902.87, an increase of 1.87% from ¥5,609,578,430.23 at the end of the previous year[5] - The equity attributable to shareholders increased by 2.07% to ¥4,656,139,140.86 from ¥4,561,801,820.95 at the end of the previous year[5] - Total assets increased to ¥5,714,284,902.87 from ¥5,609,578,430.23, marking a growth of 1.86%[29] - The company's equity attributable to shareholders rose to ¥4,656,139,140.86 from ¥4,561,801,820.95, an increase of 2.07%[29] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥209,403,725.24, an improvement of 9.12% compared to a net outflow of ¥230,425,614.28 in the same period last year[5] - The net cash flow from operating activities was -209,403,725.24, an improvement from -230,425,614.28 in the previous period[40] - Cash and cash equivalents at the end of the period were ¥1,475,802,109.55, down from ¥1,619,154,719.36 at the beginning of the year, indicating a decrease of 8.87%[24] - The net cash flow from investing activities was -$76.48 million, a decrease from -$332.65 million year-over-year[43] - The net cash flow from financing activities improved to $146.77 million from -$123.89 million year-over-year[43] Revenue Sources - Revenue from the medical industry reached 433.05 million RMB, accounting for 93.53% of total operating revenue, up from 90.10% in the same period last year, with a year-on-year growth of 19.49%[21] Expenses - Total operating costs amounted to ¥343,652,104.79, up from ¥317,308,649.52, reflecting a year-over-year increase of 8.29%[30] - Research and development expenses increased to 48,849,670.94 from 43,848,136.87, representing an increase of approximately 11.43%[37] - The company reported a decrease in sales expenses to 33,090,463.14 from 39,097,265.20, a reduction of about 15.5%[37] - The financial expenses showed a significant improvement, with a net expense of -1,284,568.97 compared to -3,025,972.68, indicating a reduction of approximately 57.5%[37] Customer and Market Development - The company launched an information solution for cabin hospitals, successfully helping multiple regions implement rapid information systems[23] - The company won a new bid for the operation and maintenance service project of the Jiangxi Province medical insurance platform, marking a breakthrough in provincial-level medical insurance projects[23] - The company added over 30 new customers for its cloud-based products, enhancing market penetration[23] Recognition and Achievements - The company was recognized as a "2021 Leader in Per-Acre Efficiency" in Zhejiang Province, highlighting its operational excellence[23] - The "5G Difficult Disease Diagnosis and Remote Multidisciplinary Collaboration Platform" project was included in the "Zhejiang Manufacturing Boutique" list for 2021[23] Other Financial Metrics - The basic and diluted earnings per share remained stable at 0.06 for both periods[37] - The company received 9,514,071.77 in tax refunds, down from 12,235,237.82, a decrease of about 22.2%[40] - Cash outflow from investing activities totaled $419.55 million, compared to $1.20 billion in the previous period[43] - Cash outflow related to financing activities was $3.23 million, significantly lower than $150.77 million in the previous period[43] - The company did not conduct an audit for the first quarter report[44]

Financial Performance - The total operating revenue for 2021 was ¥1,898,976,983.54, representing a year-over-year increase of 16.30% from ¥1,632,841,326.43 in 2020[38]. - The net profit attributable to shareholders for 2021 was ¥413,039,235.38, which is a 24.28% increase compared to ¥332,337,424.49 in 2020[38]. - The net profit after deducting non-recurring gains and losses was ¥387,332,119.99, up 23.11% from ¥314,615,081.36 in the previous year[38]. - The basic earnings per share for 2021 was ¥0.27, an increase of 17.39% from ¥0.23 in 2020[38]. - The total assets at the end of 2021 amounted to ¥5,609,578,430.23, reflecting a growth of 6.87% from ¥5,249,128,741.16 at the end of 2020[38]. - The net assets attributable to shareholders increased by 10.20% to ¥4,561,801,820.95 from ¥4,139,652,614.13 in 2020[38]. - The cash flow from operating activities for 2021 was ¥176,219,111.83, a decrease of 35.05% compared to ¥271,326,850.03 in 2020[38]. - The diluted earnings per share for 2021 was ¥0.27, which is a 22.73% increase from ¥0.22 in 2020[38]. - The weighted average return on equity for 2021 was 9.44%, down from 10.44% in 2020[38]. - The total non-operating income for 2021 was ¥25,707,115.39, compared to ¥17,722,343.13 in 2020, indicating a growth of approximately 45.0%[47]. Market Position and Strategy - The company plans to strengthen its market position and enhance profitability by expanding its product line and health service ecosystem in response to national policies and macroeconomic changes[20]. - The company is expanding its main business from product development and sales to include system construction, service, and operation across various fields such as smart healthcare and medical big data[8]. - The company aims to enhance R&D efforts by increasing investment in human resources and funding, and strengthening collaborations with renowned universities and research institutions[5]. - The company is committed to continuous innovation and product development to adapt to changing market demands and enhance its service offerings[19]. - The company aims to enhance its service offerings and market position through strategic initiatives and technological advancements in response to evolving industry demands[57]. Risks and Challenges - The company faces risks from intensified market competition, necessitating proactive management measures and increased R&D investment to maintain core competitive advantages[9]. - The company acknowledges the risk of talent loss due to intense competition in the healthcare IT sector and plans to implement strategies to retain core personnel[15]. - The company is addressing the risk of goodwill impairment from acquisitions by enhancing post-merger management and resource integration[17]. - The company recognizes the seasonal fluctuations in its operations, particularly in the second half of the year, and is taking measures to balance project implementation and cash collection[14]. - The healthcare information technology industry faces challenges such as low standardization and a fragmented market with many small players, leading to inefficiencies in product and service implementation[56]. R&D and Innovation - R&D investment amounted to 316.03 million yuan, an increase of 15.98% compared to the previous year, with 3 new invention patents and about 90 new software copyrights added[174]. - The company is currently working on five major R&D projects aimed at enhancing product competitiveness and addressing industry challenges[198]. - The company emphasizes independent research and development, utilizing a CMMI5 software maturity development process to ensure high-quality product delivery[145]. - The company has developed over 300 self-owned products and holds approximately 800 software copyrights and 21 invention patents, establishing a strong market position in the healthcare information technology sector[146]. Government Policies and Market Trends - The company is positioned to benefit from favorable government policies aimed at promoting healthcare information technology development[52]. - The healthcare information technology market in China is projected to reach ¥84.57 billion by 2025, driven by increasing IT spending in hospitals and community healthcare[51]. - The government has set specific targets for the development of smart hospitals and the integration of new technologies like AI and 5G in healthcare, which will drive industry growth[64][67]. - The company is aligned with national policies promoting the digitalization of healthcare services and the establishment of a robust public health system[64][68]. Product and Service Development - The company has established a comprehensive product system with over 300 self-developed products in the medical and health informationization application software service sector[120]. - The company has initiated a cloud transformation strategy called "HuiKang Cloud 2.0," aiming to transition from a traditional IT service provider to a technology cloud ecosystem enterprise[57]. - The company is implementing a cloud transformation strategy called "HuiKang Cloud 2.0," focusing on market-oriented development and customer needs[118]. - The company aims to achieve full cloud-based business capabilities through years of research and development in cloud technology and multi-modal intelligent connections[119]. - The company has developed a hybrid cloud internet hospital solution that integrates internet medical services with a hybrid cloud system, allowing for data sharing and customized services[133]. Community and Health Services - The company has established a comprehensive health information service system, focusing on population health needs and integrating various health data resources[126]. - The company has completed multiple health information platform projects, including electronic health card platforms and regional data centers, benefiting local communities[129]. - The company is committed to enhancing the capabilities of county-level public hospitals and promoting smart hospital construction as part of its strategic initiatives[102]. - The company is actively exploring innovative diversified elderly medical care service models, including "Internet + nursing services"[114]. - The company aims to achieve nationwide coverage of DRG/DIP payment methods by the end of 2025, ensuring comprehensive coverage of eligible medical institutions[106].

Financial Performance - The company's revenue for Q3 2021 was ¥431,494,954.02, representing a 5.60% increase year-over-year, while the year-to-date revenue reached ¥1,209,502,704.67, up 8.20% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2021 was ¥87,509,738.63, a 16.87% increase year-over-year, with a year-to-date net profit of ¥230,023,276.20, reflecting a 37.33% increase[4] - The net profit excluding non-recurring gains and losses for Q3 2021 was ¥87,419,001.63, up 22.14% year-over-year, while the year-to-date figure was ¥203,636,307.39, an increase of 26.86%[4] - Total operating revenue for the period reached ¥1,209,502,704.67, an increase from ¥1,117,806,170.80 in the previous period, representing a growth of approximately 8.5%[32] - The net profit for the current period is approximately ¥231.35 million, an increase from ¥172.04 million in the previous period, representing a growth of 34.5%[35] - The total profit before tax for the current period is approximately ¥256.21 million, compared to ¥192.55 million in the previous period, representing an increase of 33.1%[35] Assets and Liabilities - The company's total assets at the end of Q3 2021 were ¥5,164,533,306.56, a decrease of 1.61% from the end of the previous year[4] - Total liabilities decreased to ¥781,571,148.95 from ¥1,072,361,689.28, a reduction of approximately 27.1%[30] - The company's total assets decreased to ¥5,164,533,306.56 from ¥5,249,128,741.16, a decline of about 1.6%[30] - The total non-current liabilities rose to ¥6,081,612.36 from ¥3,905,669.27, an increase of approximately 55.8%[30] - The cash and cash equivalents at the end of the period amount to approximately ¥1.24 billion, down from ¥1.34 billion at the end of the previous period[45] Shareholder Information - The company has a total of 38,444 common shareholders at the end of the reporting period[13] - The largest shareholder, Ge Hang, holds 16.85% of the shares, totaling 261,070,324 shares[13] - The second-largest shareholder, Fujian Jiaying Huiju Investment Co., Ltd., holds 7.94% of the shares, totaling 123,003,913 shares[13] - The total number of shares subject to lock-up commitments is 240,475,752, with 1,513,590 shares released from lock-up in the current period[22] - The company reported a total of 15,028,455 shares under the stock incentive plan, with 1,455,090 shares released in the current period[22] Cash Flow - Cash flow from operating activities showed a net outflow of ¥248,968,547.98, which is a 24.73% decrease year-over-year[4] - The total cash flow from operating activities for the current period is approximately -¥248.97 million, compared to -¥199.60 million in the previous period, showing a decline in cash flow[42] - The total cash inflow from investment activities for the current period is approximately ¥1.64 billion, compared to ¥804.76 million in the previous period, reflecting a significant increase[42] - The net cash flow from financing activities for the current period is approximately -¥167.13 million, compared to an inflow of ¥1.20 billion in the previous period, indicating a shift in financing strategy[42] Research and Development - Research and development expenditures increased by 106.35% year-over-year, indicating a focus on innovation and new product development[9] - Research and development expenses for the period were ¥136,146,832.70, compared to ¥105,907,110.37 in the previous period, reflecting a rise of approximately 28.5%[32] Market and Strategic Initiatives - The company is implementing the "Huikang Cloud" overall transformation strategy to enhance collaboration among hospitals, patients, and third-party health service providers[12] - The company is focusing on the integration of online and offline services in the healthcare sector, responding to higher industry demands for smart hospital information systems[12] - The company is focusing on expanding its market presence and exploring new strategic initiatives[23] Investment and Assets Management - The company reported a significant increase in investment income, which grew by 609.70% year-over-year, primarily due to the disposal of a subsidiary's equity[9] - The company reported a 90.26% decrease in cash paid for investment activities, reflecting a reduction in external equity investments[11] - The company planned a major asset restructuring with Weining Health Technology Group, which was later terminated[23] - The company has received inquiries from the Shenzhen Stock Exchange regarding its restructuring plans[23] Miscellaneous - The company did not conduct an audit for the third quarter report[53] - The company has not disclosed any new product or technology developments in the current report[51] - There were no significant market expansion or acquisition strategies mentioned in the third quarter report[51]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion yuan for the first half of 2021, representing a year-on-year growth of 25%[1] - The company achieved operating revenue of CNY 778,007,750.65, representing a 9.70% increase compared to the same period last year[41] - Net profit attributable to shareholders reached CNY 142,513,537.57, a growth of 53.87% year-on-year[41] - The net profit after deducting non-recurring gains and losses was CNY 116,217,305.76, up 30.66% from the previous year[41] - The company reported a basic earnings per share of CNY 0.09, an increase of 50.00% compared to the same period last year[41] - The total assets at the end of the reporting period were CNY 5,038,748,580.80, a decrease of 4.01% from the end of the previous year[41] - The net assets attributable to shareholders were CNY 4,251,790,412.67, reflecting a 2.71% increase year-on-year[41] - The net cash flow from operating activities was CNY -242,234,432.39, an improvement of 10.82% compared to the previous year[41] Research and Development - The company plans to invest 200 million yuan in research and development for new products and technologies in the upcoming year, aiming to enhance its competitive edge in the market[1] - R&D investment reached 12,939.09 million yuan, a year-on-year increase of 13.90%[62] - The company is actively pursuing collaborations with top universities and research institutions to foster innovation and product development[1] - The company is committed to continuous innovation and product development to meet the evolving needs of the healthcare sector[62] Market Expansion and Strategy - Future outlook includes a projected revenue growth of 15% for the second half of 2021, driven by increased demand for healthcare information technology solutions[1] - The company is focusing on market expansion, targeting a 20% increase in its market share within the next two years through strategic partnerships and collaborations[1] - The company has initiated a merger with a leading healthcare data analytics firm, which is expected to enhance its service offerings and operational capabilities[1] - The company is implementing a cloud transformation strategy with "HuiKang Cloud 2.0" to enhance market share[49] Product Development and Services - The company aims to strengthen its presence in the Internet healthcare sector, with a goal of launching three new innovative solutions by the end of 2021[1] - The company has established a comprehensive product system with over 300 self-developed products in the medical and health information application software service sector[52] - The company launched the "HuiKang Cloud 2.0" development strategy, aiming to build a complete medical and health application service cloud platform[63] - The "HuiKang Cloud 2.0" includes cloud-based solutions such as the cloud HIS overall solution, which integrates various medical services and improves operational efficiency[64] User Growth and Engagement - User data indicates that the company has expanded its user base to over 5 million active users, marking a 30% increase compared to the previous year[1] - The "健康中山" APP has registered over 2 million users, with an average daily active user count of about 120,000, and has facilitated over 23 million appointment bookings[74] Financial Management and Investments - The company is committed to maintaining a robust financial position, with plans to reinvest profits into business development rather than distributing cash dividends[1] - The company has committed investment projects totaling 1,317.61 million yuan, with 1,288.77 million yuan invested and 292.08 million yuan in progress[148] - The company has utilized 105.89 million yuan of raised funds to replace self-raised funds previously invested in projects, including 80.29 million yuan for the data integration-driven intelligent health cloud service project[154] Risk Management - The company acknowledges potential risks related to market competition and is implementing strategies to mitigate these risks through enhanced research and development efforts[1] - The focus on network security and data protection measures is being strengthened to safeguard personal information[84] Community and Social Responsibility - The company actively participated in poverty alleviation efforts, successfully helping a village in Hubei Province achieve poverty alleviation[183]

Financial Performance - The company's operating revenue for Q1 2021 was ¥402,209,573.15, representing a 22.75% increase compared to ¥327,652,582.46 in the same period last year[7] - Net profit attributable to shareholders for Q1 2021 was ¥90,363,704.15, a significant increase of 55.85% from ¥57,979,998.79 in the previous year[7] - The basic earnings per share for Q1 2021 increased to ¥0.08, up 60.00% from ¥0.05 in the same period last year[7] - Operating revenue for the reporting period reached 402.21 million yuan, a year-on-year increase of 22.75%; net profit attributable to shareholders after deducting non-recurring gains and losses was 83.88 million yuan, up 53.02% year-on-year[27] - Net profit for Q1 2021 reached CNY 91,657,485.18, representing a 54.5% increase from CNY 59,235,559.15 in Q1 2020[59] - The total comprehensive income attributable to the parent company was CNY 90.36 million, compared to CNY 57.98 million in the previous year, marking a 55.7% increase[64] Cash Flow and Liquidity - The net cash flow from operating activities for Q1 2021 was -¥230,425,614.28, an improvement from -¥280,815,511.15 in the previous year[7] - Cash and cash equivalents decreased by 40.38% compared to the beginning of the year, primarily due to loan repayments, payment of goods, employee salaries, and investment in financial products[23] - The cash flow from operating activities showed a net outflow of CNY 230.43 million, an improvement from a net outflow of CNY 280.82 million in the same period last year[69] - The total cash and cash equivalents at the end of the period were 526,419,223.24 CNY, down from 148,372,033.13 CNY in the previous period[75] - The company's cash and cash equivalents decreased by 620,122,326.65 CNY during the period, compared to a decrease of 7,556,852.36 CNY in the previous period[75] Assets and Liabilities - Total assets at the end of Q1 2021 were ¥5,070,225,115.05, a decrease of 3.41% from ¥5,249,128,741.16 at the end of the previous year[7] - The company's total assets decreased to CNY 4,824,820,181.80 from CNY 4,965,332,733.18, a decline of 2.8%[54] - Total liabilities decreased to CNY 731,156,395.50 from CNY 942,234,989.50, a reduction of 22.4%[54] - The company's total current liabilities decreased to CNY 769,326,041.64 from CNY 1,068,456,020.01, a reduction of about 28.03%[48] - The company's equity increased to CNY 4,093,663,786.30 from CNY 4,023,097,743.68, an increase of 1.7%[54] Investments and Expenditures - The company’s development expenditure increased by 40.13% compared to the beginning of the year, mainly due to increased capitalized R&D investment[23] - Cash paid for investments decreased by 87.71% year-on-year, primarily due to payments made for subsidiary acquisitions in the previous period[25] - Cash paid for the construction of fixed assets, intangible assets, and other long-term assets increased by 81.61% year-on-year, mainly due to an increase in payments for ongoing projects[25] - The total amount of raised funds was 128.88 million yuan, with 19.57 million yuan invested in the current quarter and a cumulative investment of 50.98 million yuan[31] Shareholder Information - The total number of shareholders at the end of the reporting period was 34,971, with the largest shareholder holding 16.84% of the shares[12] - The net assets attributable to shareholders at the end of Q1 2021 were ¥4,232,710,614.45, reflecting a 2.25% increase from ¥4,139,652,614.13 at the end of the previous year[7] - The company's minority shareholders' equity increased by 72.70% compared to the beginning of the year, mainly due to investments received from minority shareholders[23] Research and Development - Research and development expenses for Q1 2021 were CNY 43,848,136.87, compared to CNY 35,499,420.16 in the previous year, indicating a growth of 23.5%[57] - The company has initiated a comprehensive cloud transformation strategy called "HuiKang Cloud," aiming to enhance product R&D capabilities and service quality[27] Market and Strategic Initiatives - The company secured six million-level orders in the first quarter, indicating a strong demand in the medical informationization sector[27] - The company has won strategic bids for provincial medical insurance projects in Hebei, Gansu, and Tianjin, laying the groundwork for future city-level project acquisitions[27] - The company has adjusted the implementation method of the "Data Fusion-Driven Intelligent Health Cloud Service Overall Solution Project" to self-build a health technology product industrialization base[34] Other Income and Expenses - The company reported a significant increase in other income, which rose to CNY 11.10 million from CNY 9.49 million, a growth of 17%[62] - The company received CNY 12.24 million in tax refunds, up from CNY 6.34 million in the same period last year, indicating a 93.5% increase[69] - The financial expenses showed a reversal, with a net income of CNY 2.86 million compared to an expense of CNY 2.21 million in the previous year[62]